Literature DB >> 33215304

Identification of the immune gene expression signature associated with recurrence of high-grade gliomas.

Adria-Jaume Roura1, Bartlomiej Gielniewski1, Paulina Pilanc1, Paulina Szadkowska1, Marta Maleszewska1, Sylwia K Krol1, Ryszard Czepko2, Wojciech Kaspera3, Bartosz Wojtas4, Bozena Kaminska1.   

Abstract

High-grade gliomas (HGGs), the most common and aggressive primary brain tumors in adults, inevitably recur due to incomplete surgery or resistance to therapy. Intratumoral genomic and cellular heterogeneity of HGGs contributes to therapeutic resistance, recurrence, and poor clinical outcomes. Transcriptomic profiles of HGGs at recurrence have not been investigated in detail. Using targeted sequencing of cancer-related genes and transcriptomics, we identified single nucleotide variations, small insertions and deletions, copy number aberrations (CNAs), as well as gene expression changes and pathway deregulation in 16 pairs of primary and recurrent HGGs. Most of the somatic mutations identified in primary HGGs were not detected after relapse, suggesting a subclone substitution during the tumor progression. We found a novel frameshift insertion in the ZNF384 gene which may contribute to extracellular matrix remodeling. An inverse correlation of focal CNAs in EGFR and PTEN genes was detected. Transcriptomic analysis revealed downregulation of genes involved in messenger RNA splicing, cell cycle, and DNA repair, while genes related to interferon signaling and phosphatidylinositol (PI) metabolism are upregulated in secondary HGGs when compared to primary HGGs. In silico analysis of the tumor microenvironment identified M2 macrophages and immature dendritic cells as enriched in recurrent HGGs, suggesting a prominent immunosuppressive signature. Accumulation of those cells in recurrent HGGs was validated by immunostaining. Our findings point to a substantial transcriptomic deregulation and a pronounced infiltration of immature dendritic cells in recurrent HGG, which may impact the effectiveness of frontline immunotherapies in the GBM management. KEY MESSAGES: Most of the somatic mutations identified in primary HGGs were not detected after relapse. Focal CNAs in EGFR and PTEN genes are inversely correlated in primary and recurrent HGGs. Transcriptomic changes and distinct immune-related signatures characterize HGG recurrence. Recurrent HGGs are characterized by a prominent infiltration of immature dendritic and M2 macrophages.

Entities:  

Keywords:  Copy number aberrations; Immune signature; Immunohistochemistry; Recurrent high-grade glioma; Tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33215304     DOI: 10.1007/s00109-020-02005-7

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  40 in total

1.  Molecular definition of the pro-tumorigenic phenotype of glioma-activated microglia.

Authors:  Aleksandra Ellert-Miklaszewska; Michal Dabrowski; Maciej Lipko; Marcin Sliwa; Marta Maleszewska; Bozena Kaminska
Journal:  Glia       Date:  2013-05-07       Impact factor: 7.452

2.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

Review 4.  Glioblastoma targeted therapy: updated approaches from recent biological insights.

Authors:  M Touat; A Idbaih; M Sanson; K L Ligon
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

5.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

6.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.

Authors:  Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

Review 7.  Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.

Authors:  Dominik Sturm; Sebastian Bender; David T W Jones; Peter Lichter; Jacques Grill; Oren Becher; Cynthia Hawkins; Jacek Majewski; Chris Jones; Joseph F Costello; Antonio Iavarone; Kenneth Aldape; Cameron W Brennan; Nada Jabado; Stefan M Pfister
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

8.  Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.

Authors:  Hoon Kim; Siyuan Zheng; Seyed S Amini; Selene M Virk; Tom Mikkelsen; Daniel J Brat; Jonna Grimsby; Carrie Sougnez; Florian Muller; Jian Hu; Andrew E Sloan; Mark L Cohen; Erwin G Van Meir; Lisa Scarpace; Peter W Laird; John N Weinstein; Eric S Lander; Stacey Gabriel; Gad Getz; Matthew Meyerson; Lynda Chin; Jill S Barnholtz-Sloan; Roel G W Verhaak
Journal:  Genome Res       Date:  2015-02-03       Impact factor: 9.043

Review 9.  Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.

Authors:  Zhenyi An; Ozlem Aksoy; Tina Zheng; Qi-Wen Fan; William A Weiss
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

10.  Longitudinal molecular trajectories of diffuse glioma in adults.

Authors:  Floris P Barthel; Kevin C Johnson; Frederick S Varn; Anzhela D Moskalik; Georgette Tanner; Emre Kocakavuk; Kevin J Anderson; Olajide Abiola; Kenneth Aldape; Kristin D Alfaro; Donat Alpar; Samirkumar B Amin; David M Ashley; Pratiti Bandopadhayay; Jill S Barnholtz-Sloan; Rameen Beroukhim; Christoph Bock; Priscilla K Brastianos; Daniel J Brat; Andrew R Brodbelt; Alexander F Bruns; Ketan R Bulsara; Aruna Chakrabarty; Arnab Chakravarti; Jeffrey H Chuang; Elizabeth B Claus; Elizabeth J Cochran; Jennifer Connelly; Joseph F Costello; Gaetano Finocchiaro; Michael N Fletcher; Pim J French; Hui K Gan; Mark R Gilbert; Peter V Gould; Matthew R Grimmer; Antonio Iavarone; Azzam Ismail; Michael D Jenkinson; Mustafa Khasraw; Hoon Kim; Mathilde C M Kouwenhoven; Peter S LaViolette; Meihong Li; Peter Lichter; Keith L Ligon; Allison K Lowman; Tathiane M Malta; Tali Mazor; Kerrie L McDonald; Annette M Molinaro; Do-Hyun Nam; Naema Nayyar; Ho Keung Ng; Chew Yee Ngan; Simone P Niclou; Johanna M Niers; Houtan Noushmehr; Javad Noorbakhsh; D Ryan Ormond; Chul-Kee Park; Laila M Poisson; Raul Rabadan; Bernhard Radlwimmer; Ganesh Rao; Guido Reifenberger; Jason K Sa; Michael Schuster; Brian L Shaw; Susan C Short; Peter A Sillevis Smitt; Andrew E Sloan; Marion Smits; Hiromichi Suzuki; Ghazaleh Tabatabai; Erwin G Van Meir; Colin Watts; Michael Weller; Pieter Wesseling; Bart A Westerman; Georg Widhalm; Adelheid Woehrer; W K Alfred Yung; Gelareh Zadeh; Jason T Huse; John F De Groot; Lucy F Stead; Roel G W Verhaak
Journal:  Nature       Date:  2019-11-20       Impact factor: 69.504

View more
  4 in total

1.  ZNF384: A Potential Therapeutic Target for Psoriasis and Alzheimer's Disease Through Inflammation and Metabolism.

Authors:  Shougang Liu; Xiuqing Yuan; Hang Su; Fanghua Liu; Zhe Zhuang; Yongfeng Chen
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

2.  PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas.

Authors:  Kirsi J Rautajoki; Serafiina Jaatinen; Aliisa M Tiihonen; Matti Annala; Elisa M Vuorinen; Anni Kivinen; Minna J Rauhala; Kendra K Maass; Kristian W Pajtler; Olli Yli-Harja; Pauli Helén; Joonas Haapasalo; Hannu Haapasalo; Wei Zhang; Matti Nykter
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

3.  Improvements in Quality Control and Library Preparation for Targeted Sequencing Allowed Detection of Potentially Pathogenic Alterations in Circulating Cell-Free DNA Derived from Plasma of Brain Tumor Patients.

Authors:  Paulina Szadkowska; Adria-Jaume Roura; Bartosz Wojtas; Kamil Wojnicki; Sabina Licholai; Tomasz Waller; Tomasz Gubala; Kacper Zukowski; Michal Karpeta; Kinga Wilkus; Wojciech Kaspera; Sergiusz Nawrocki; Bozena Kaminska
Journal:  Cancers (Basel)       Date:  2022-08-12       Impact factor: 6.575

4.  Circular RNA: A novel type of biomarker for glioma (Review).

Authors:  Wei Sun; Huandi Zhou; Xuetao Han; Liubing Hou; Xiaoying Xue
Journal:  Mol Med Rep       Date:  2021-06-24       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.